Compounded Tirzepatide vs Zepbound: Cost and Differences in 2026

In 2024 the choice looked obvious. Compounded tirzepatide sold for as little as $99 a month against a Zepbound sticker price above $1,086 [1]. A tenfold gap is not a decision; it is an answer.

In 2026 the arithmetic is different, and the comparison is genuinely close. This page lays out what actually separates the two, with the hidden fees included.

What are we actually comparing?

Zepbound is Eli Lilly’s FDA-approved tirzepatide product for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro is the same molecule approved for type 2 diabetes. They are the only FDA-approved tirzepatide products in the United States.

Compounded tirzepatide is a preparation a pharmacy makes, typically from bulk tirzepatide powder, often with an added ingredient, supplied as a multi-dose vial with separate syringes. It is not FDA-approved and is not a generic.

That distinction is not a technicality. FDA states plainly that it does not review compounded drugs for safety, effectiveness or quality before they are marketed [2].

What does each one cost in 2026?

Branded Zepbound

Lilly publishes its self-pay prices [3]:

Dose	Self Pay Journey Program	Regular price outside the program
2.5 mg	$299/month	$299/month
5 mg	$399/month	$399/month
7.5 mg	$449/month	$599/month
10 mg	$449/month	$699/month
12.5 mg	$449/month	$849/month
15 mg	$449/month	$1,049/month

Lilly cut these tiers on December 1, 2025, from $349/$499/$499 to $299/$399/$449 [3]. The $449 column is the Zepbound Self Pay Journey Program price: Lilly’s own announcement says it applies “only on first fill and when prescriptions are refilled within 45 days of their previous delivery,” and gives the regular prices in the right-hand column. Older pages and some dispensing pharmacies still print $499 and $699 as the out-of-window figures; the ones above are Lilly’s. A “month” is 28 days, which is four single-dose vials or one KwikPen.

Since March 2026 the same self-pay prices have also been available at major retail pharmacies for the KwikPen, using a Lilly savings card open to all patients including the uninsured.

With commercial insurance that covers Zepbound, the manufacturer savings card can bring a fill to as little as $25 a month. That is a savings-card tier rather than a cash price, and it is the cheapest route on this page for anyone eligible.

Compounded tirzepatide

There is no published price, because there is no single seller. Checking providers’ own pages on September 14, 2026, all-in monthly costs for compounded tirzepatide programs run roughly from $169 to $450 once a required membership fee is included, with individual providers at very different points in that band:

• Mochi Health: $90 medication plus a $79 membership ($39 the first month), about $169 all-in at the starting dose. Both figures confirmed on joinmochi.com; Mochi’s banner shows $199 struck through as the former medication price, so older quotes are stale.
• Ivim Health: $133 medication plus a $75 membership, about $208 all-in at the starting dose — but the $133 is a six-month plan price, not a month-to-month rate, and Ivim’s first month of membership is free. Quoting $133 without the six-month commitment overstates how easy that price is to get.
• Eden: $199 medication plus a $99 membership, $298 all-in. Confirmed on tryeden.com, where the membership is $39 the first month. The advertised link carries a promotional coupon, so treat $199 as a promotional rather than a standing rate.
• Zealthy: from $216 medication plus a $135 membership, about $351 all-in. The $39-first-month and $135-ongoing membership is confirmed in Zealthy’s own press releases, but zealthy.com was unreachable on September 14, 2026 and the $216 is a third-party directory figure described there as requiring quarterly purchase. An earlier 2026 capture gives $329 month-to-month instead, so treat the medication side as a range.
• Henry Meds: oral tirzepatide only, reported at $1,047 for a three-month supply or $891 prepaid, so $349 or $297 a month with no separate membership. Henry publishes no price on its own site — every figure here is a third-party capture — and the same $297 appears elsewhere in directories as an injectable semaglutide monthly price, which suggests at least one of the two attributions is wrong.

Every one of those is provider-published or directory-reported rather than manufacturer-published, none is audited, and several are explicitly starting prices that rise as a person titrates upward. Providers that gate pricing behind an intake questionnaire — MEDVi among them — could not be verified at all, and no figure should be published for them.

So the honest headline is: the ranges overlap. Compounded tirzepatide is often somewhat cheaper. It is no longer dramatically cheaper, and for some programs at maintenance doses it is not cheaper at all.

Why do advertised compounded prices mislead?

Four structural reasons. Understanding them is worth more than memorizing any specific number.

1. Medication versus membership. Some platforms quote the drug price and bill a separate monthly membership. Eden, checked on September 14, 2026, lists medication at $199 a month plus a mandatory $99 membership — an all-in of $298, not $199. Earlier comparison pages that omitted the membership understated the cost by a third.

2. Dose-tier pricing. Some programs charge more as your dose rises. Most people titrate upward over months. A platform advertising a 2.5 mg starter price is quoting a dose the label describes as treatment initiation, not maintenance — so the advertised figure is a price you pay for roughly four weeks and then never again.

3. Prepaid plans presented as monthly rates. A “$149 a month” plan billed as a single annual charge is a four-figure upfront commitment. Several providers’ terms state that unused months and unused medication are not refunded.

4. Billing cycles of 28 days, not calendar months. A program billed every four weeks charges thirteen times a year, not twelve. That is roughly an extra month’s cost that never appears in the monthly comparison.

When you compare, insist on one number: the all-in total for twelve months at the dose you expect to be on.

Is there a difference in what’s in the vial?

Yes, and this is where the comparison stops being about money.

Active ingredient. Zepbound contains tirzepatide base, the form studied in Lilly’s clinical trials. Some compounded products and gray-market powders use salt forms instead. FDA has stated it is not aware of any lawful basis for using salt forms in compounding, and the Connecticut Attorney General’s 2025 notice to clinics specifically cited salt forms of semaglutide and tirzepatide sourced from overseas manufacturers with thin inspection records [4]. No published trial has tested a tirzepatide salt in humans.

Additives. Many compounded products add vitamin B12, niacinamide, levocarnitine or glycine. A JAMA Health Forum secret-shopper study published July 17, 2026 found 58.7 percent of 75 surveyed clinics confirming an additive, B vitamins in 56.0 percent of cases [5]. No clinical trial has tested tirzepatide plus a vitamin additive. In March 2026 Lilly reported that its testing of compounded tirzepatide-B12 products found a previously unidentified impurity formed by a reaction between the two, at levels up to 10 percent of total protein content in the samples tested, and called for a recall; the compounding trade group disputed the claims [6].

Potency. Approved products are made under federal manufacturing rules with batch release testing. Compounded products depend on the individual pharmacy. A January 2026 FDA warning letter to one compounding pharmacy described tirzepatide lots testing at 86.8 and 89.1 percent of label strength, and a tirzepatide-glycine-methylcobalamin lot that failed sterility testing and was distributed anyway [7].

Sterility. In the JAMA Health Forum study, four of 23 analyzed supplying compounding facilities were not licensed to perform sterile compounding at all [5]. A registered outsourcing facility recalled a tirzepatide injection lot in October 2025 for lack of sterility assurance and received a warning letter in April 2026 [8].

What about the weight-loss results?

This is the most common marketing error in the category, and FDA has treated it as a violation.

The SURMOUNT trials tested Lilly’s approved tirzepatide. Those results belong to that product at those doses. They do not describe a compounded preparation with a different concentration, an added vitamin and unverified potency.

FDA’s March 3, 2026 announcement of 30 warning letters to telehealth companies identified exactly this problem: claims implying sameness with FDA-approved products, and marketing that obscures sourcing by putting the telehealth firm’s own brand name on a compounded drug as though the firm were the compounder [9]. Law firm analysis of the letters found FDA treats brand comparisons and “generic” terminology as implying FDA approval, which makes the product misbranded [10].

Some providers publish their own member-reported outcomes for compounded products, with a disclosure that compounded GLP-1s are not FDA-approved or evaluated for safety or efficacy. Self-reported program data is not a clinical trial, and should not be read as one.

What about safety reports?

FDA had received more than 730 adverse event reports tied to compounded tirzepatide as of May 31, 2026, alongside 990 for compounded semaglutide — more than 1,700 combined [11]. FDA says the true figure is likely higher, because state-licensed pharmacies that are not outsourcing facilities are not required to report adverse events. Many of the reported events resemble those seen with the approved products.

FDA also flags a problem the branded supply chain does not have: fraudulent labels. Some compounded vials name a pharmacy that does not exist, or a real pharmacy that did not make the product [2]. That defeats the most obvious check a patient can perform.

What about the legal difference?

Branded Zepbound is lawful, full stop.

Compounded tirzepatide sits in a narrow lane. The shortage-based pathway that allowed mass compounding closed when FDA declared the tirzepatide shortage resolved in 2024, and the Fifth Circuit upheld that decision on August 27, 2026. What remains is Section 503A patient-specific compounding, which requires a prescriber to document a clinical difference the approved product cannot meet for that individual patient. Cost is not a qualifying reason.

FDA has separately proposed to exclude tirzepatide from the 503B bulks list permanently; the comment period closed July 30, 2026 with no final decision as of September 14, 2026.

Practically, that means a compounded tirzepatide supply can end abruptly. That is a real cost of the cheaper option: continuity risk.

Side by side

	Compounded tirzepatide	Branded Zepbound
FDA-approved	No	Yes
Typical cash cost	~$169–$450/month all-in, from providers’ own pages	$299–$449/month on the Self Pay Journey Program; $599–$1,049 at higher doses outside it; as little as $25 with covered insurance and the savings card
Price stable across doses	Varies; some flat, many are starting prices that rise with dose	Tiered, capped at $449 only with an on-time refill
Insurance	Generally not covered	Can be covered; savings card available
Medicare	Not covered by the GLP-1 Bridge	KwikPen covered at $50 copay for eligible Part D members
Device	Usually multi-dose vial plus syringes	Single-dose vial, single-dose pen, or multi-dose KwikPen
Potency and sterility testing	Depends entirely on the pharmacy	Manufacturer quality standards apply
Clinical trial evidence	None for the compounded preparation	SURMOUNT program
Supply continuity	At regulatory risk	Stable
Legal basis	Narrow 503A patient-specific pathway only	Approved product

How do I decide?

Not on price alone, and not from any single page. Some practical steps:

1. Check insurance before anything else. A covered plan plus the savings card is cheaper than every compounded program on the market.
2. Price the branded route honestly. $299 for a starter dose and $449 at maintenance with the refill window respected — $599 to $1,049 at maintenance doses if you miss it.
3. Get the compounded all-in number. Medication plus membership, at your expected maintenance dose, times twelve or thirteen depending on the billing cycle.
4. Ask who makes it. Legal name, state, sterile compounding license, 503A or 503B status. Then verify with the state board.
5. Ask what is in it. Tirzepatide base or a salt form. Additives, and why.
6. Ask for a certificate of analysis matched to your lot and dated within six months.
7. Ask your prescriber the clinical question directly: what documented reason makes the FDA-approved product unsuitable for me? If there is not one, the 503A pathway is not really being used.
8. Read the refund terms on any prepaid plan before paying.

The bottom line

The cost gap that built the compounded tirzepatide market has narrowed but has not closed at the bottom. Manufacturer self-pay pricing at $299 to $449 a month sits inside the same band as several compounded programs once their membership fees are counted, and well below some of them at maintenance doses — but the cheapest verified compounded programs still start near $169 a month all-in.

What has not closed is the oversight gap. One product is reviewed before it is sold; the other is not. One has trial data; the other borrows it. One has a stable legal footing; the other depends on a narrow exception under active regulatory pressure.

None of that tells you what to do. Whether a GLP-1 is right for you, and which product fits your situation, is a conversation for a healthcare provider who knows your history.

Sources

1. Eli Lilly sues companies selling alternative versions of its weight loss drug — NPR
2. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
3. Authentic Zepbound (tirzepatide) Shipped to You — LillyDirect
4. Connecticut Attorney General letter to weight loss clinics and spas (May 21, 2025)
5. DiStefano MJ et al., Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand, JAMA Health Forum 2026;7(7):e262207
6. Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks — Reuters
7. FDA Warning Letter Breakdown: Sterility Failures, Subpotent GLP-1 Drugs — The FDA Group
8. FDA warning letter to ProRx LLC, MARCS-CMS 723704 (April 7, 2026)
9. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s
10. GLP-1 Compliance: FDA Targets Telehealth Marketing in 30 New Warning Letters — Foley & Lardner
11. FDA warns on compounded GLP-1s amid 1,700-plus safety reports — Becker’s
12. Weight loss drugs — Medicare.gov
13. Outsourcing Facilities Association v. FDA, No. 25-10600 (5th Cir. Aug. 27, 2026)